Clinical trial · Interventional
A Study of Comparing Effects of Thulium Laser en Bloc Resection and Electrical Transurethral Resection of the Non-muscle Invasive Bladder Cancer
NCT02951078CI-TRIAL-00024552unknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is to verify the short-term efficacy and long-term prognosis of thulium laser resection compared with conventional transurethral resection of non-muscular invasive bladder cancer. Half of participants will receive thulium laser resection of bladder cancer, while the other half will receive electrical transurethral resection of bladder cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Electrical transurethral resection of bladder tumor | Procedure | — | UNRESOLVED |
| Thulium Laser en Bloc Resection of bladder tumor | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Thulium Laser en Bloc Resection of bladder tumor
- description
- Thulium Laser en Bloc Resection of the Non-muscle Invasive Bladder tumor with thulium laser
- interventionNames
- Procedure: Thulium Laser en Bloc Resection of bladder tumor
- type
- ACTIVE_COMPARATOR
- label
- Electrical transurethral resection of bladder tumor
- description
- Electrical transurethral resection of the Non-muscle Invasive Bladder tumor
- interventionNames
- Procedure: Electrical transurethral resection of bladder tumor
Primary outcomes (1)
- measure
- The residual rate of tumor in the second operation of the two surgical methods
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: 1. Pathological or histological diagnosis of primary non-muscle invasive bladder urothelial carcinoma (TaTisT1); 2. Imaging examinations showed the bladder muscle has not been affected, no lymph node metastasis or distant metastasis; 3. Patients who agree to TURBT surgery, and will be effected to the postoperative follow-up treatment such as conventional infusion after the operation; 4. Function of main organs (heart, liver, lung, kidney) should be normal, PS score 0-2; 5. Bladder capacity≥ 200ml. Exclusion Criteria: 1. Find distant metastasis ,infiltration of the surrounding organs or relapse before operation.Metastatic bladder cancer or other cancers involve the bladder; 2. Received chemotherapy or BCG perfusion therapy in the nearly 3 months; 3. Patients who can not tolerate the serious side effects during the bladder perfusion treatment process (bladder irritation and other symptoms); 4. Patients during pregnancy ,critical care patients and patients who have other cases of surgical contraindications.Such as serious cardiovascular disease,coagulation abnormalities,non-transitional epithelial tumors( such as adenocarcinoma and squamous cell carcinoma),acute cystitis,can not be supine because of spinal deformity,untreated urethral stricture.
References
Publications (0)
Data not yet available
No reference posted for this study.